Connect with us

Health

AbbVie Inc (NYSE:ABBV) Major Events From The Third Quarter

Published

on

AbbVie Inc (NYSE:ABBV) reported positive top-line data from three pivotal Phase III clinical trials assessing risankizumab, an investigational IL-23 inhibitor, compared to adalimumab and ustekinumab for the treatment of people with moderate-to-severe chronic plaque psoriasis.

Data of the three studies demonstrated that risankizumab fulfilled all co-primary and graded secondary endpoints, attaining considerably greater rates of almost clear or clear skin at week 16 compared to adalimumab and ustekinumab. The safety profile was steady with all previously reported trials, and there were no fresh safety indications detected across the three trials. Risankizumab is being advanced in collaboration with Boehringer Ingelheim.

The key events

AbbVie reported positive top-line data from the Phase III SELECT-BEYOND clinical study assessing upadacitinib, in patients with moderate-to-severe rheumatoid arthritis who failed to adequately respond or were not tolerant to treatment with biologic DMARDs.

Data demonstrated that following 12-weeks of treatment, both once-daily administration of upadacitinib (30 mg and 15 mg) met the trial’s main endpoints of low disease activity and ACR20. All ranked secondary endpoints were attained with both measures. The safety profile of upadacitinib was steady with previously announced Phase 2 studies and the Phase III SELECT-NEXT clinical study, with no new safety indications detected. Detailed study outcomes will be presented at an imminent medical conference.

AbbVie reported positive top-line data from the Phase IIb randomized, placebo-controlled, dose-ranging trial of upadacitinib in adult people with moderate-to-severe atopic dermatitis not adequately checked by topical treatments, or for whom such treatments were not medically suggested. Results in all doses at week 16 demonstrated that patients cured with upadacitinib attained statistically notable improvements, versus placebo, in the primary and all itch-specific and skin secondary endpoints. In addition, reduction in itch was seen within the initial week and improvement in skin within the preliminary two weeks.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of journaltranscript.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure

BRANDS

DETAILS

SCORE

PRODUCT SITES

  • Certified Organic
  • Made In U.S.A
  • Purity Promise
  • Price From $49

9.8

30% OFF Today! “30 0FF”

  • All Natural
  • Made In U.S.A
  • Lab Tested
  • Price From $69

9.7

  • All Natural
  • Made In U.S.A
  • Dissolvable Oral
  • Price From $99

9.6

  • All Natural
  • Made In U.S.A
  • Oral Mist
  • Price From $39

9.5

BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Purity Promise
  • Price From $49
SCORE

9.8

PRODUCT SITE
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Lab Tested
  • Price From $69
SCORE

9.7

PRODUCT SITE VIEW PRODUCTS
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Dissolvable Oral
  • Price From $99
SCORE

9.6

PRODUCT SITE VIEW PRODUCTS
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Oral Mist
  • Price From $39
SCORE

9.5

PRODUCT SITE VIEW PRODUCTS
Advertisement
Advertisement

Symbol        Alert        High        Gain

 

  VBIO          $0.67       $4.10      500%

  IMLFF        $0.11       $0.57      400%

  CMXC        $0.25       $0.45      80%

  REPCF       $0.54       $0.79      48%

 

Get Your Latest Winner Delivered to Your Inbox!

FREE

For The Next 48 Hours

Advertisement
Advertisement
Advertisement
Advertisement
Advertisement